Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHVNOTCMKTS:CYDYNASDAQ:DYNNASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$15.43-1.1%$18.21$14.33▼$55.70$1.58B0.951.27 million shs1.36 million shsCYDYCytoDyn$0.35-0.6%$0.31$0.10▼$0.49$441.39M1.293.25 million shs598,653 shsDYNDyne Therapeutics$14.41-0.3%$11.19$6.36▼$47.45$1.64B1.171.69 million shs1.75 million shsTARSTarsus Pharmaceuticals$40.89-0.1%$45.56$20.08▼$57.28$1.72B0.83700,731 shs716,491 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven-1.05%-9.21%-20.93%-47.25%-54.32%CYDYCytoDyn-0.59%+0.97%-17.18%+35.92%+157.77%DYNDyne Therapeutics-0.35%-1.97%+23.16%+19.59%-56.35%TARSTarsus Pharmaceuticals-0.15%-6.90%-4.69%-14.97%+24.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHVNBiohaven2.987 of 5 stars4.51.00.00.01.82.50.6CYDYCytoDyn0.0482 of 5 stars0.02.00.00.00.60.00.0DYNDyne Therapeutics2.6724 of 5 stars4.50.00.00.02.23.30.0TARSTarsus Pharmaceuticals2.3499 of 5 stars3.50.00.00.03.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHVNBiohaven 3.07Buy$59.46285.46% UpsideCYDYCytoDyn 0.00N/AN/AN/ADYNDyne Therapeutics 3.00Buy$44.93211.79% UpsideTARSTarsus Pharmaceuticals 3.00Buy$66.6763.04% UpsideCurrent Analyst Ratings BreakdownLatest CYDY, TARS, BHVN, and DYN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025DYNDyne TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$37.006/2/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$60.00 ➝ $34.006/2/2025TARSTarsus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$75.005/29/2025DYNDyne TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$46.005/27/2025TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$72.005/19/2025BHVNBiohavenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.005/13/2025BHVNBiohavenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025BHVNBiohavenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$61.00 ➝ $54.005/9/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$46.00 ➝ $38.005/9/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.005/5/2025TARSTarsus PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$46.00 ➝ $51.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHVNBiohavenN/AN/AN/AN/A$5.34 per shareN/ACYDYCytoDyn$270K1,634.77N/AN/A($0.11) per share-3.21DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/ATARSTarsus Pharmaceuticals$233.67M7.35N/AN/A$5.95 per share6.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHVNBiohaven-$408.17M-$9.36N/AN/AN/AN/A-225.12%-158.89%8/5/2025 (Estimated)CYDYCytoDyn-$49.84M-$0.01N/A∞N/AN/AN/A-76.70%8/14/2025 (Estimated)DYNDyne Therapeutics-$235.94M-$3.59N/AN/AN/AN/A-57.46%-51.62%8/11/2025 (Estimated)TARSTarsus Pharmaceuticals-$135.89M-$2.73N/AN/AN/A-103.64%-55.86%-39.28%8/6/2025 (Estimated)Latest CYDY, TARS, BHVN, and DYN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025BHVNBiohaven-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/1/2025Q1 2025TARSTarsus Pharmaceuticals-$0.69-$0.64+$0.05-$0.64$72.50 million$78.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHVNBiohavenN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHVNBiohavenN/A2.892.89CYDYCytoDynN/A0.350.35DYNDyne TherapeuticsN/A17.0217.02TARSTarsus Pharmaceuticals0.305.425.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHVNBiohaven88.78%CYDYCytoDyn5.06%DYNDyne Therapeutics96.68%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipBHVNBiohaven16.00%CYDYCytoDyn0.54%DYNDyne Therapeutics14.14%TARSTarsus Pharmaceuticals8.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHVNBiohaven239102.11 million84.94 millionOptionableCYDYCytoDyn201.25 billion1.22 billionNot OptionableDYNDyne Therapeutics100113.67 million80.63 millionOptionableTARSTarsus Pharmaceuticals5042.01 million35.07 millionOptionableCYDY, TARS, BHVN, and DYN HeadlinesRecent News About These CompaniesTarsus Pharmaceuticals CCO sells $765,800 in stockJune 13 at 3:58 AM | investing.comTarsus Pharmaceuticals CCO sells $765,800 in stockJune 13 at 3:58 AM | investing.comAssenagon Asset Management S.A. Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)June 12 at 5:58 AM | marketbeat.comE. Ohman J or Asset Management AB Boosts Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)June 7, 2025 | marketbeat.comSquarepoint Ops LLC Sells 51,329 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)June 7, 2025 | marketbeat.comStocks Showing Improving Market Leadership: Tarsus Pharmaceuticals Earns 87 RS RatingJune 6, 2025 | msn.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Time to Sell?June 5, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)June 5, 2025 | marketbeat.comWellington Management Group LLP Sells 8,552 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)June 4, 2025 | marketbeat.comOppenheimer Begins Coverage on Tarsus Pharmaceuticals (NASDAQ:TARS)June 4, 2025 | americanbankingnews.comTarsus Pharmaceuticals assumed with an Outperform at OppenheimerJune 2, 2025 | msn.comTarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by OppenheimerJune 2, 2025 | marketbeat.comNuveen Asset Management LLC Sells 15,186 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 31, 2025 | marketbeat.comQ2 Earnings Forecast for TARS Issued By HC WainwrightMay 30, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Ameriprise Financial Inc.May 30, 2025 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesMay 29, 2025 | globenewswire.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Position Lessened by Two Sigma Advisers LPMay 29, 2025 | marketbeat.comTwo Sigma Investments LP Has $5.05 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 29, 2025 | marketbeat.comTarsus Pharmaceuticals' (TARS) Buy Rating Reaffirmed at HC WainwrightMay 28, 2025 | marketbeat.comTarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)May 27, 2025 | benzinga.comTFG Asset Management GP Ltd Sells 414,117 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYDY, TARS, BHVN, and DYN Company DescriptionsBiohaven NYSE:BHVN$15.43 -0.16 (-1.05%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$15.44 +0.01 (+0.06%) As of 06/13/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.CytoDyn OTCMKTS:CYDY$0.35 0.00 (-0.59%) As of 06/13/2025 03:59 PM EasternCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Dyne Therapeutics NASDAQ:DYN$14.41 -0.05 (-0.35%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$14.40 -0.01 (-0.03%) As of 06/13/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Tarsus Pharmaceuticals NASDAQ:TARS$40.89 -0.06 (-0.15%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$40.88 -0.01 (-0.02%) As of 06/13/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
